Search

Your search keyword '"Troupioti, P"' showing total 2 results
Start Over Author "Troupioti, P" Journal antimicrobial agents and chemotherapy
2 results on '"Troupioti, P"'

1. Clinical Isolates of Mycobacterium tuberculosisin Four European Hospitals Are Uniformly Susceptible to Benzothiazinones

Author

Pasca, Maria Rosalia, Degiacomi, Giulia, Ribeiro, Ana Luisa de Jesus Lopes, Zara, Francesca, De Mori, Patrizia, Heym, Beate, Mirrione, Maurizio, Brerra, Roberto, Pagani, Laura, Pucillo, Leopoldo, Troupioti, Panajota, Makarov, Vadim, Cole, Stewart T., and Riccardi, Giovanna

Abstract

ABSTRACTThe new antitubercular drug candidate 2-[2-S-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one (BTZ043) targets the DprE1 (Rv3790) subunit of the enzyme decaprenylphosphoryl-β-d-ribose 2′-epimerase. To monitor the potential development of benzothiazinone (BTZ) resistance, a total of 240 sensitive and multidrug-resistant Mycobacterium tuberculosisclinical isolates from four European hospitals were surveyed for the presence of mutations in the dprE1gene and for BTZ susceptibility. All 240 strains were susceptible, thus establishing the baseline prior to the introduction of BTZ043 in clinical trials.

Published
2010
Full Text
View/download PDF

2. Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones.

Author

Pasca MR, Degiacomi G, Ribeiro AL, Zara F, De Mori P, Heym B, Mirrione M, Brerra R, Pagani L, Pucillo L, Troupioti P, Makarov V, Cole ST, and Riccardi G

Subjects
Base Sequence, DNA Primers genetics, DNA, Bacterial genetics, Drug Resistance, Multiple, Bacterial genetics, Europe, Genes, Bacterial, Humans, In Vitro Techniques, Microbial Sensitivity Tests, Mutation, Mycobacterium tuberculosis enzymology, Mycobacterium tuberculosis genetics, Racemases and Epimerases genetics, Antitubercular Agents pharmacology, Mycobacterium tuberculosis drug effects, Mycobacterium tuberculosis isolation & purification, Spiro Compounds pharmacology, Thiazines pharmacology, Tuberculosis, Multidrug-Resistant drug therapy, Tuberculosis, Multidrug-Resistant microbiology
Abstract

The new antitubercular drug candidate 2-[2-S-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one (BTZ043) targets the DprE1 (Rv3790) subunit of the enzyme decaprenylphosphoryl-beta-d-ribose 2'-epimerase. To monitor the potential development of benzothiazinone (BTZ) resistance, a total of 240 sensitive and multidrug-resistant Mycobacterium tuberculosis clinical isolates from four European hospitals were surveyed for the presence of mutations in the dprE1 gene and for BTZ susceptibility. All 240 strains were susceptible, thus establishing the baseline prior to the introduction of BTZ043 in clinical trials.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results